Carcinoembryonic Antigen

CEA belongs to the immunoglobulin superfamily and was first described in 1965 as a protein present in fetal colon tissue and colorectal carcinoma but absent from healthy adult colon. It is a GPI-anchored cell surface glycoprotein that participates in intercellular adhesion, and its overexpression in cancer may facilitate tumor cell aggregation and metastasis. In clinical practice, serum CEA is measured by immunoassay, with values below 5.0 ng/mL generally considered normal in non-smokers. Smokers may have slightly higher baseline levels due to non-malignant CEA expression in bronchial epithelium.

CEA is most established as a monitoring tool rather than a screening or diagnostic biomarker. In colorectal cancer, preoperative CEA level has prognostic significance — higher levels are associated with more advanced stage and worse outcomes. After curative surgery, CEA should decline to normal levels within 4 to 6 weeks; failure to normalize suggests residual disease. During follow-up surveillance, a rising CEA is one of the earliest indicators of recurrence and may prompt imaging studies and consideration of further treatment.

Beyond colorectal cancer, elevated CEA is associated with pancreatic cancer, gastric cancer, breast cancer, and lung adenocarcinoma, though its sensitivity for these cancers is lower and its clinical role is less well-defined. Non-malignant conditions including inflammatory bowel disease, pancreatitis, liver cirrhosis, and heavy smoking can also cause CEA elevation, reinforcing that CEA should be interpreted as a trend over time and in the context of the full clinical picture rather than as a standalone diagnostic value.

Prevena Health is exploring whether continuous CEA monitoring may enable earlier detection of recurrence-related trends compared to quarterly blood draws. The clinical value of CEA in colorectal cancer surveillance depends on identifying a rising trajectory, but measurements spaced months apart may delay detection of inflection points. Continuous surveillance through a wearable platform aims to provide the temporal resolution needed to identify early upward trends before they reach conventional alarm thresholds.

This approach may also support research into whether more granular CEA kinetic data — including rate of rise, pattern of fluctuation, and response to interventions — can improve the specificity of CEA-based surveillance and reduce the frequency of false-positive imaging workups that single-point elevations sometimes trigger. Prevena's goal is to complement established surveillance protocols with continuous molecular trend data.